bioAffinity Technologies Advances Asthma Diagnostic Platform with Sputum-Based Therapy Matching
Event summary
- bioAffinity Technologies presented research at the AAAAI 2026 annual meeting on March 1, 2026, demonstrating its diagnostic platform's ability to identify antibody drug receptors in sputum for asthma therapies dupilumab and benralizumab.
- The company's proprietary flow cytometry platform, equipped with AI analysis, aims to guide personalized treatment decisions for asthma and COPD patients.
- bioAffinity's CyPath® Lung test, already commercialized for early lung cancer detection, achieved 92% sensitivity, 87% specificity, and 88% accuracy in clinical studies.
The big picture
bioAffinity Technologies is expanding its diagnostic capabilities beyond lung cancer into respiratory diseases, aligning with the broader trend toward personalized medicine in chronic conditions. The company's AI-driven approach positions it in a growing market for non-invasive, data-rich diagnostics that aim to reduce trial-and-error in treatment selection. With asthma and COPD affecting 650 million people globally, the potential scale of impact is substantial.
What we're watching
- Clinical Validation
- How the pace of clinical validation for the asthma diagnostic platform will impact its commercialization timeline.
- Market Adoption
- Whether physicians will widely adopt sputum-based diagnostics for personalized asthma therapy matching.
- Competitive Positioning
- The extent to which bioAffinity can leverage its existing CyPath® Lung infrastructure to accelerate the rollout of its asthma diagnostic platform.
Related topics